Zacks Research Weighs in on AstraZeneca PLC’s Q2 2025 Earnings (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Investment analysts at Zacks Research cut their Q2 2025 earnings per share estimates for AstraZeneca in a research note issued on Wednesday, April 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.14 for the quarter, down from their previous estimate of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.63 EPS, Q1 2026 earnings at $1.20 EPS and FY2026 earnings at $5.09 EPS.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The business had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. During the same period in the previous year, the business posted $0.69 earnings per share. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Morgan Stanley began coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating on the stock. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.00.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $68.36 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64. The business’s 50 day moving average price is $66.12 and its 200-day moving average price is $65.87. The firm has a market capitalization of $211.94 billion, a PE ratio of 35.60, a P/E/G ratio of 1.25 and a beta of 0.50. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $76.56.

AstraZeneca Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were given a $0.965 dividend. The ex-dividend date was Thursday, February 22nd. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a dividend yield of 2.3%. AstraZeneca’s dividend payout ratio is 100.52%.

Institutional Trading of AstraZeneca

A number of large investors have recently made changes to their positions in AZN. Oppenheimer & Co. Inc. raised its stake in AstraZeneca by 51.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 14,424 shares of the company’s stock valued at $977,000 after acquiring an additional 4,919 shares during the last quarter. Cerity Partners LLC raised its stake in AstraZeneca by 113.0% during the 4th quarter. Cerity Partners LLC now owns 95,677 shares of the company’s stock valued at $6,444,000 after acquiring an additional 50,750 shares during the last quarter. Barclays PLC raised its stake in AstraZeneca by 317.4% during the 3rd quarter. Barclays PLC now owns 1,242,431 shares of the company’s stock valued at $84,136,000 after acquiring an additional 944,765 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in AstraZeneca by 43.7% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 163,011 shares of the company’s stock valued at $10,979,000 after acquiring an additional 49,541 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in AstraZeneca during the 3rd quarter valued at approximately $2,241,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.